Primary neuroprotection: The holy grail of multiple sclerosis therapy

Neurology

Volumn 74, Issue 13, 2010, Pages 1018-1019

  Fox, Robert J ^a  

^a Mellen Center for Multiple Sclerosis Treatment and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; IBUDILAST; MITOXANTRONE; RITUXIMAB;

BRAIN ATROPHY; DISABILITY; DRUG EFFICACY; EDITORIAL; HUMAN; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; NEUROPROTECTION; OLIGODENDROGLIA; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT OUTCOME;

EID: 77950244111     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d6b165     Document Type: Editorial

References (7)

1. Barkhof F, Hulst HE, Drulović J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 2010;74:1033-1040.
2. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a: Multiple Sclerosis Collaborative Research Group. Neurology 2000;55:185-192.
3. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-733.
4. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8:382-397.
5. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol (Berl) 1989;77: 569-575.
6. Sebastiani G, Morissette C, Lagacé C, et al. The cAMP-specific phosphodiesterase 4B mediates Abeta-induced mi-croglial activation. Neurobiol Aging 2006;27:691-701.
7. Wakita H, Tomimoto H, Akiguchi I, et al. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res 2003;992:53-59